Topics

NuCana plc: NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

07:05 EDT 25 Oct 2019 | FinanzNachrichten

Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin Primary Endpoints of Overall Survival and Objective Response Rate Three Inte...

Original Article: NuCana plc: NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

NEXT ARTICLE

More From BioPortfolio on "NuCana plc: NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer"

Quick Search